UA103191C2 - Производные арилпиразинона как стимуляторы секреции инсулина, способ их получения (варианты) и их применение для лечения диабета - Google Patents

Производные арилпиразинона как стимуляторы секреции инсулина, способ их получения (варианты) и их применение для лечения диабета

Info

Publication number
UA103191C2
UA103191C2 UAA201014234A UAA201014234A UA103191C2 UA 103191 C2 UA103191 C2 UA 103191C2 UA A201014234 A UAA201014234 A UA A201014234A UA A201014234 A UAA201014234 A UA A201014234A UA 103191 C2 UA103191 C2 UA 103191C2
Authority
UA
Ukraine
Prior art keywords
diabetes
preparation
treatment
insulin secretion
processes
Prior art date
Application number
UAA201014234A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джерард Боттон
Эрик Валеур
Кристина Шарон
Мишелина Кергоат
Самер Элбаваб
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of UA103191C2 publication Critical patent/UA103191C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Данное изобретение касается производных арилпиразинона формулы (I), где R1, R2, R3 и А имеют значения, указанные в пункте 1, как стимуляторов секреции инсулина.Изобретение также касается получения и применения этих производных пиразинона для профилактики и/или лечения диабета и связанных патологий.
UAA201014234A 2008-04-29 2009-03-31 Производные арилпиразинона как стимуляторы секреции инсулина, способ их получения (варианты) и их применение для лечения диабета UA103191C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08008165 2008-04-29
PCT/EP2009/002328 WO2009132739A1 (en) 2008-04-29 2009-03-31 Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (1)

Publication Number Publication Date
UA103191C2 true UA103191C2 (ru) 2013-09-25

Family

ID=40589704

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201014234A UA103191C2 (ru) 2008-04-29 2009-03-31 Производные арилпиразинона как стимуляторы секреции инсулина, способ их получения (варианты) и их применение для лечения диабета

Country Status (25)

Country Link
US (2) US8815859B2 (ru)
EP (1) EP2268624B1 (ru)
JP (1) JP5498482B2 (ru)
KR (1) KR101687419B1 (ru)
CN (1) CN102015661B (ru)
AR (1) AR071518A1 (ru)
AU (1) AU2009242720B2 (ru)
BR (1) BRPI0910833A2 (ru)
CA (1) CA2722813C (ru)
CO (1) CO6310997A2 (ru)
CY (1) CY1114531T1 (ru)
DK (1) DK2268624T3 (ru)
EA (1) EA022345B1 (ru)
EC (1) ECSP10010642A (ru)
ES (1) ES2433210T3 (ru)
HR (1) HRP20130992T1 (ru)
IL (1) IL208959A (ru)
MX (1) MX2010011792A (ru)
NZ (1) NZ589555A (ru)
PL (1) PL2268624T3 (ru)
PT (1) PT2268624E (ru)
SI (1) SI2268624T1 (ru)
UA (1) UA103191C2 (ru)
WO (1) WO2009132739A1 (ru)
ZA (1) ZA201008505B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736472A1 (en) * 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013066838A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62198671A (ja) 1986-02-25 1987-09-02 Toyo Jozo Co Ltd １−置換アルキル１，２−ジヒドロ−２−ピラジノン誘導体
CA2446980A1 (en) * 2001-05-14 2002-11-21 Argyrios G. Arvanitis Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
NZ537629A (en) 2002-07-19 2007-05-31 Biovitrum Ab Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders
FR2857867B1 (fr) * 2003-07-25 2005-10-14 Oreal Utilisation en coloration capillaire de derives de ninhydrine portant un groupe heteroalkyle
EP1732564A1 (en) 2004-03-29 2006-12-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
NZ555419A (en) * 2004-11-03 2009-07-31 Curis Inc Mediators of the hedgehog gene signaling pathways, compositions and uses related thereto
TW200640881A (en) * 2005-02-15 2006-12-01 Du Pont Fungicidal pyrazine derivatives
ES2412007T3 (es) 2005-12-21 2013-07-09 Janssen Pharmaceutica, N.V. Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1
AU2007261461A1 (en) 2006-06-21 2007-12-27 E. I. Du Pont De Nemours And Company Pyrazinones as cellular proliferation inhibitors

Also Published As

Publication number Publication date
CA2722813C (en) 2017-03-21
WO2009132739A1 (en) 2009-11-05
IL208959A (en) 2015-09-24
EP2268624A1 (en) 2011-01-05
JP5498482B2 (ja) 2014-05-21
EA022345B1 (ru) 2015-12-30
US20110046159A1 (en) 2011-02-24
PL2268624T3 (pl) 2014-01-31
JP2011518847A (ja) 2011-06-30
CN102015661B (zh) 2014-05-14
ECSP10010642A (es) 2010-12-30
HRP20130992T1 (hr) 2013-11-22
CY1114531T1 (el) 2016-10-05
EP2268624B1 (en) 2013-07-31
ES2433210T3 (es) 2013-12-09
EA201001688A1 (ru) 2011-06-30
NZ589555A (en) 2012-08-31
ZA201008505B (en) 2012-01-25
MX2010011792A (es) 2010-11-25
BRPI0910833A2 (pt) 2015-08-11
KR101687419B1 (ko) 2016-12-19
SI2268624T1 (sl) 2013-12-31
DK2268624T3 (da) 2013-11-04
CO6310997A2 (es) 2011-08-22
CA2722813A1 (en) 2009-11-05
AU2009242720B2 (en) 2014-03-27
US8815859B2 (en) 2014-08-26
US20140329837A1 (en) 2014-11-06
AU2009242720A1 (en) 2009-11-05
IL208959A0 (en) 2011-01-31
US9233937B2 (en) 2016-01-12
CN102015661A (zh) 2011-04-13
KR20100135313A (ko) 2010-12-24
AR071518A1 (es) 2010-06-23
PT2268624E (pt) 2013-11-07

Similar Documents

Publication Publication Date Title
MX2010009576A (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
IN2012DN01233A (ru)
IL185808A0 (en) Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
MX2010009575A (es) Derivados de pirazinonas como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX2012001070A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
NZ601121A (en) 5-alkynyl-pyrimidines
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
MX2010009922A (es) Activadores de piridazinona glucocinasa.
MX2013003034A (es) Lactamas piperidinilo-substituidas como moduladores de gpr119.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
MX2010009577A (es) Derivados de piridopirazinona que estimulan la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
MX342947B (es) Tratamiento de diabetes tipo 2.
UA103191C2 (ru) Производные арилпиразинона как стимуляторы секреции инсулина, способ их получения (варианты) и их применение для лечения диабета
MX2010009837A (es) Tiazolil-dihidro-indazoles.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
TN2011000531A1 (en) 5- alkynyl - pyridines
MX2010009999A (es) Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad.